[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346394-105":59,"doc-detail-346394-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","iaps-in-cancers-molecular-mechanisms-clinical-prognostic-value-and-translational-therapeutic-potential","IAPs in cancers - molecular mechanisms, clinical prognostic value, and translational therapeutic potential","","Conventional cancer therapies often yield only limited prognostic benefit, despite rapid progress in molecular biology and multi-omics that has accelerated targeted treatment. Inhibitor of apoptosis proteins (IAPs) have been identified as critical regulators across experimental and clinical research. Key barriers include tumor heterogeneity, adverse events from IAP inhibitor drugs, and insufficient validated biomarkers for patient selection. This review consolidates IAP domains, functions, biological processes, and translational drug development toward improved therapeutic strategies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/iaps-in-cancers-molecular-mechanisms-clinical-prognostic-value-and-translational-therapeutic-potential/346394/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/iaps-in-cancers-molecular-mechanisms-clinical-prognostic-value-and-translational-therapeutic-potential/346394.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are current conventional cancer therapies often insufficient?","Question",{"text":113,"@type":114},"They usually deliver only modest improvements in prognosis and treatment outcomes are limited by multidrug resistance, recurrence, and a high share of unresectable or metastatic cases.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What challenges hinder IAP-targeted therapy adoption?",{"text":118,"@type":114},"Tumor heterogeneity, adverse effects linked to IAP inhibitor drugs (such as cytokine release and inflammation), and the lack of validated biomarkers for selecting appropriate patients.",{"name":120,"@type":111,"acceptedAnswer":121},"How does this review position IAPs in cancer treatment development?",{"text":122,"@type":114},"It summarizes IAP structural domains, molecular functions, biological processes, and clinical relevance, then links these insights to drug development and translational applications to refine IAP-related therapeutic strategies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346394,1790618011,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":24,"preview_urls":147},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Teng et al. Journal of Translational Medicine (2026) 24:143  \n[https://doi.org/10.1186/s12967-025-07640-7](https://doi.org/10.1186/s12967-025-07640-7)  \nJournal of Translational Medicine  \nREVIEW Open Access  \nIAPs in cancers: molecular mechanisms, clinical prognostic value, and translational therapeutic potential  \nZhisheng Teng 1, Liyun Teng2* and Jing Xie3*  \nAbstract  \nBackground Conventional therapies remain the primary approach for most cancers but typically achieve only modest improvements in prognosis. With the rapid advances in molecular biology and multi-omics technologies, targeted therapy has become the first choice for treating advanced cancer. Among these, inhibitor of apoptosis proteins (IAPs) has emerged as critical regulators in both experimental and clinical studies.  \nMain body Nevertheless, several challenges persist, including tumor heterogeneity across cancer types, adverse effects associated with IAPs inhibitors (such as cytokine release and inflammation), and the lack of validated biomarkers for patient selection. With the development of artificial intelligence and precision medicine, IAP-targeted therapy, especially in combination with other therapies, has shown favorable clinical application potential. Conclusions: This review systematically summarizes the structural domains, molecular functions, biological processes, clinical relevance, and advances in drug development and translational applications of IAPs, aiming torefine therapeutic strategies and facilitate clinical translation.  \nKeywords Inhibitor of apoptosis proteins (IAPs), Ubiquitination, Cell death, Innate and adaptive immunity, IAPs inhibitors  \n*Correspondence: Liyun Teng [714304393@qq.com](714304393@qq.com)[ ](714304393@qq.com)Jing Xie [xiejing@wmu.edu.cn](xiejing@wmu.edu.cn)  \n1Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China  \n2Department of Obstetrics and Gynecology, The Chinese Medicine Hospital of Yongjia County, Wenzhou, China  \n3Department of Stomatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China  \nIntroduction  \nCancer remains a major global health challenge due to its biological heterogeneity, complex etiologies, and diverse clinical manifestations [1] Despite advances in surgery, radiotherapy, and chemotherapy, treatment efficacy is frequently limited by multidrug resistance, tumor recurrence, and the high proportion of patients who present with unresectable or metastatic disease [2]. Achieving selective tumor cell eradication while minimizing systemic toxicity therefore remains a central but unresolved clinical objective [3].  \nThe rapid development of molecular oncology has enabled the identification of actionable biomarkers and therapeutic targets, promoting a shift toward personalized and mechanism-driven cancer therapies [4].  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nTeng et al. Journal of Translational Medicine (2026) 24:143  \nAmong these targets, the Inhibitor of Apoptosis Proteins (IAPs), also referred to as BIR-repeat containing proteins (","cbCaik0mkUhYLtI1","https://ap.wps.com/l/cbCaik0mkUhYLtI1","pdf",3635119,44,"English","# Abstract\n# Introduction\n# IAPs as molecular regulators\n# Translational roadmap and therapeutic strategies","[{\"question\":\"Why are current conventional cancer therapies often insufficient?\",\"answer\":\"They usually deliver only modest improvements in prognosis and treatment outcomes are limited by multidrug resistance, recurrence, and a high share of unresectable or metastatic cases.\"},{\"question\":\"What challenges hinder IAP-targeted therapy adoption?\",\"answer\":\"Tumor heterogeneity, adverse effects linked to IAP inhibitor drugs (such as cytokine release and inflammation), and the lack of validated biomarkers for selecting appropriate patients.\"},{\"question\":\"How does this review position IAPs in cancer treatment development?\",\"answer\":\"It summarizes IAP structural domains, molecular functions, biological processes, and clinical relevance, then links these insights to drug development and translational applications to refine IAP-related therapeutic strategies.\"}]","IAPs in cancers - molecular mechanisms, clinical prognostic value, and translational therapeutic potential | PDF",1790061250,111,[148,152,156,160,164],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2666b0f4c1192f56c0d23e45949ae7d.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57915feb24f8e30e72d97e6ddd1e62a4.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/934ecd34f47d408e869706347f93c059.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edb90662d0dedb4a110455fc4990c91c.webp",980,1306,{"page_no":24,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/acad7f0a868452c8e0b52fc5a710998d.webp",979,1305]